Peer-reviewed veterinary case report
Barazone reduces itching and skin lesions in dogs with atopic
By Ahlstrom, L A et al.·Published in Journal of veterinary pharmacology and therapeutics·2010·School of Veterinary Science, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Barazone decreases skin lesions and pruritus and increases quality of life in dogs with atopic dermatitis: a randomized, blinded, placebo-controlled trial.
- Species:
- dog
Plain-English summary
A group of dogs with atopic dermatitis (a skin allergy) were treated with a new leave-on conditioner called Barazone to see if it could help reduce their itching and skin lesions. Over six weeks, the dogs showed significant improvements in their skin condition and overall quality of life compared to those who received a placebo. Owners reported less itching and better daily comfort for their pets. Barazone was well-tolerated, and the dogs did not experience any major side effects.
People also search for: dog itching treatment · atopic dermatitis in dogs · Barazone for dog skin problems
Abstract
A randomized, blinded, placebo-controlled study was conducted to assess the efficacy of a new 0.025% budesonide leave-on-conditioner (Barazone) in controlling the clinical signs of canine atopic dermatitis (AD). Twenty-nine dogs with AD were randomly allocated to receive 3 weeks of once-weekly treatment with either Barazone or Placebo and then were crossed-over to receive the alternative treatment for a further 3 weeks. At the start and end of each treatment phase, referring veterinarians performed a dermatological and general physical examination on each dog, assigned a Lesional Score, collected blood for haematological and biochemical analyses and rated the dog's overall tolerance to the preceding treatment. Owners assessed their dog's level of pruritus and quality of life (QoL) daily, using visual analogue scales labelled with behavioural descriptors. Barazone improved skin lesions (P = 0.02) and QoL (P < 0.001) and reduced pruritus (P ≤ 0.002) compared with treatment with Placebo. There were no significant differences in the tolerance scores and only minor differences in the general physical examination findings and haematological and biochemical parameters between dogs receiving Barazone or Placebo. This study demonstrated that Barazone, applied once weekly at 1 g/kg for 3 weeks, was an efficacious treatment for the control of the clinical signs of AD in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21062310/